|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19:a phase 1 clinical trial显示文摘No effective drug treatments are available for coronavirus disease 2019(COVID-19).Host-directed therapies targeting the underlying aberrant immune responses leading to pulmonary tissue damage,death,or long-term functional disability in survivors require clinical evaluation.We performed a parallel assigned controlled,non-randomized,phase 1 clinical trial to evaluate the safety of human umbilical cord-derived mesenchymal stem cells(UC-MSCs)infusions in the treatment of patients with moderate and severe COVID-19 pulmonary disease.The study enrolled 18 hospitalized patients with COVID-19(n=9 for each group).The treatment group received three cycles of intravenous infusion of UC-MSCs(3×107 cells per infusion)on days 0,3,and 6.Both groups received standard COVID-treatment regimens.Adverse events,duration of clinical symptoms,laboratory parameters,length of hospitalization,serial chest computed tomography(CT)images,the PaO2/FiO2 ratio,dynamics of cytokines,and IgG and IgM anti-SARS-CoV-2 antibodies were analyzed.No serious UC-MSCs infusion-associated adverse events were observed.Two patients receiving UC-MSCs developed transient facial flushing and fever,and one patient developed transient hypoxia at 12 h post UC-MSCs transfusion.Mechanical ventilation was required in one patient in the treatment group compared with four in the control group.All patients recovered and were discharged.Our data show that intravenous UC-MSCs infusion in patients with moderate and severe COVID-19 is safe and well tolerated.Phase 2/3 randomized,controlled,double-blinded trials with long-term follow-up are needed to evaluate the therapeutic use of UC-MSCs to reduce deaths and improve long-term treatment outcomes in patients with serious COVID-19. | Fanping Meng Ruonan Xu Siyu Wang Zhe Xu Chao Zhang Yuanyuan Li Tao Yang Lei Shi Junliang Fu Tianjun Jiang Lei Huang Peng Zhao Xin Yuan Xing Fan Ji-Yuan Zhang Jinwen Song Dawei Zhang Yanmei Jiao Limin Liu Chunbao Zhou Markus Maeurer Alimuddin Zumla Ming Shi Fu-Sheng Wang | 2020 | Signal Transduction and Targeted Therapy2020，5，1： | 16 |
| 2 | Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients:a randomized,double-blind,placebo-controlled phase 2 trial显示文摘Treatment of severe Coronavirus Disease 2019(COVID-19)is challenging.We performed a phase 2 trial to assess the efficacy andsafety of human umbilical cord-mesenchymal stem cells(UC-MScs)to treat severe coViD-19 patients with lung damage,based onour phase 1 data.In this randomized,double-blind,and placebo-controlled trial,we recruited 101 severe coVID-19 patients withlung damage.They were randomly assigned at a 2:1 ratio to receive either UC-MSCs(4×10^(7)cells per infusion)or placebo on day 0,3,and 6.The primary endpoint was an altered proportion of whole lung lesion volumes from baseline to day 28.Other imagingoutcomes,6-minute walk test(6-MWT),maximum vital capacity,diffusing capacity,and adverse events were recorded and analyzed.In all,100 COVID-19 patients were finally received either UC-MSCs in=65)or placebo(n=35).UC-MSCs administrationexerted numerical improvement in whole lung lesion volume from baseline to day 28 compared with the placebo(the mediandifference was-13.31%,95%Cl-29.14%,2.13%,P=0.08).UC-MSCs significanty reduced the proportions of solid componentlesion volume compared with the placebo(median difference:-15.45%;95%CI-30.82%,-0.39%;P=0.043).The 6-MWT showedan increased distance in patients treated with UC-MSCs(difference:27.00 m;95%CI 0.00,57.00;P=0.057).The incidence of adverseevents was similar in the two groups.These results suggest that UC-MSCs treatment is a safe and potentially effective therapeuticapproach for COVID-19 patients with lung damage.A phase 3 trial is required to evaluate effects on reducing mortality andpreventing long-term pulmonary disability. | Lei Shi Hai Huang Xuechun Lu Xiaoyan Yan Xiaojing Jiang Ruonan Xu Siyu Wang Chao Zhang Xin Yuan Zhe Xu Lei Huang Jun-Liang Fu Yuanyuan Li Yu Zhang Wei-Qi Yao Tianyi Liu Jinwen Song Liangliang Sun Fan Yang Xin Zhang Bo Zhang Ming Shi Fanping Meng Yanning Song Yongpei Yu Jiqiu Wen Qi Li Qing Mao Markus Maeurer Alimuddin Zumla Chen Yao Wei-Fen Xie Fu-Sheng Wang | 2021 | Signal Transduction and Targeted Therapy2021，6，3： | 13 |
| 3 | Epstein-Barr virus and the origin of Hodgkin lymphoma显示文摘Although Epstein-Barr virus(EBV)is present in the malignant Hodgkin/Reed-Sternberg(HRS)cells of a proportion of cases of classical Hodgkin lymphoma(c HL),how the virus contributes to the pathogenesis of this disease remains poorly defined.It is clear from the studies of other EBV-associated cancers that the virus is usually not sufficient for tumor development and that other oncogenic co-factors are required.This article reviews what is known about the contribution of EBV to the pathogenesis of c HL and focuses on emerging evidence implicating chronic inflammation as a potential oncogenic co-factor in this malignancy. | Martina Vockerodt Fathima Zumla Cader Claire Shannon-Lowe Paul Murray | 2014 | Chinese Journal of Cancer2014，33，12： | 2 |
| 4 | Rapid and accurate detec- tion of Mycobacterium tuberculosis in sputum samples by Cephe- id Xpert MTB/RIF assay--a clinical validation study 显示文摘 | Rachow A Zumla A Heinrich N | 2011 | PLoS One2011，6，20： | 1 |
| 5 | Infection control and MERS-CoV in health-care workers显示文摘 | Zumla A Hui DS | 2014 | Lancet2014，383，9932： | 1 |
| 6 | Hajj:infectious disease surveillance and control显示文摘 | Memish ZA Zumla A Alhakeem RF | 2014 | Lancet2014，383，9934： | 1 |
| 7 | The WI-IO 2014 global tuberculosis report--further to go显示文摘 | Zumla A George A Sharma V | 2015 | Lancet Glob Health2015，3，1： | 1 |
| 8 | Gulf War syndrome: is it due to a systemic shift in cytokine balance towardsa Th2 profile 显示文摘 | Rook GA Zumla A | 1997 | Lancet1997，349，9068： | 1 |
| 9 | Diagnosis of extrapulmonary tuberculosis us- ing the Xpert() MTB/RIF assay 显示文摘 | Lawn SD Zumla AI | 2012 | Expert Rev Anti Infect Ther2012，10，6： | 1 |
| 10 | Treatment of tuberculosis: present status and future prospects 显示文摘 | Onyebujoh P Zumla A Ribeiro I | 2005 | Bull World Health Organ2005，83，11： | 1 |
| 11 | Tuberculosis 显示文摘 | Lawn S D Zumla A I | 2011 | Lancet2011，378，9785： | 1 |
| 12 | Family cluster of Middle East respiratory syndrome coronavirus infections 显示文摘 | Memish ZA Zumla AI AI-Hakeem RF | 2013 | N Engl J Med2013，368，26： | 1 |
| 13 | WHO s 2013 global report on tuberculosis: successes, threats, and opportuni- ties显示文摘 | Zumla A George A Sharma V | 2013 | Lancet2013，382，997： | 1 |
| 14 | Advances in the development of new tuberculosis drugs and treatment regimens 显示文摘 | Zumla A Nahid P Cole ST | 2013 | Nat Rev Drug Discov2013，12，5： | 1 |
| 15 | Interaction between HIV and mycobacterium tuberculosis:HIV-1-induced CD 4 T-cell de-pletion and the development of active tuberculosis显示文摘 | Geldmacher C Zumla A Hoelscher M | 2012 | Curr Opin HIV/AIDS2012，7，3： | 1 |
| 16 | Impact of HIV infection on turberculosis显示文摘 | Zumla A Malon P Henderson J | | 0，，895： | 1 |
| 17 | Immune responses to tuberculosisin developing countries: implications for new vaccines显示文摘 | ROOK G A DHEDA K ZUMLA A | 2005 | Nat Rev Immunol2005，207，5： | 1 |
| 18 | Paradox of the global emergence of tuberculous显示文摘 | Grange JM Zumla A | 1999 | Lancet1999，353，： | 1 |
| 19 | Real-time qPCR normalization ;strategies and considerations显示文摘 | HUGGETY J DGEDA K BUSTIN S ZUMLA A | 2005 | Genes Immunity2005，6，： | 1 |
| 20 | Immune responses to tuberculosis in developing countries:implications for new vaccines显示文摘 | ROOK G A DHEDA K ZUMLA A | 2005 | Nat Rev Immmunol2005，5，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员